Reshma  Kewalramani net worth and biography

Reshma Kewalramani Biography and Net Worth

Reshma Kewalramani, M.D., FASN, is the Chief Executive Officer and President at Vertex. Dr. Kewalramani has dedicated her career to improving the lives of patients, including the last 15+ years through the development of new medicines. She joined Vertex in 2017 and was previously the Chief Medical Officer and Executive Vice President of Global Medicines Development and Medical Affairs. During that time, Vertex made remarkable progress to bring new medicines to more cystic fibrosis (CF) patients around the world, including the approval of SYMDEKO/SYMKEVI and the rapid approval of TRIKAFTA to potentially treat up to 90% of all CF patients. Under Dr. Kewalramani’s leadership, Vertex also advanced several programs outside of CF into the clinic, including alpha-1 antitrypsin deficiency, APOL1-mediated kidney diseases, sickle cell disease and beta-thalassemia.

Prior to Vertex, Dr. Kewalramani spent more than 12 years at Amgen where she held a variety of roles across Research and Development, including as Vice President, Global Clinical Development, Nephrology & Metabolic Therapeutic Area and Vice President, U.S. Medical Organization, a group she established and grew to assume responsibility for the full portfolio of molecules.

Dr. Kewalramani is passionate about developing and supporting the next generation of scientists and giving back to her community. She is a member of the board of directors of the Biomedical Science Careers Program, an organization dedicated to supporting underrepresented students to pursue a career in STEM, and RIZE Massachusetts, a nonprofit foundation focused on ending the opioid epidemic.  She is also a member of Boston University School of Medicine Dean’s Advisory Board. She is a Fellow of the American Society of Nephrology and was on the inaugural Board of Directors of the Kidney Health Initiative. 

She is the recipient of the American College of Physicians Associates Council Award, the American Medical Women's Association Janet M. Glasgow Memorial Achievement Citation, and the Harvard Medical School Excellence in Teaching Award. In 2019, she was the recipient of the TiE Boston Healthcare Leadership Award and named one of Boston Business Journal’s Power 50.

Dr. Kewalramani completed her internship and residency in Internal Medicine at the Massachusetts General Hospital and her fellowship in Nephrology at the Massachusetts General Hospital and Brigham and Women’s Hospital combined program. Dr. Kewalramani received her medical degree, with honors, from the seven-year medicine program at the Boston University School of Medicine and completed the General Management Program at Harvard Business School.

What is Reshma Kewalramani's net worth?

The estimated net worth of Reshma Kewalramani is at least $51.14 million as of July 17th, 2023. Dr. Kewalramani owns 118,906 shares of Vertex Pharmaceuticals stock worth more than $51,142,660 as of February 24th. This net worth evaluation does not reflect any other investments that Dr. Kewalramani may own. Additionally, Dr. Kewalramani receives an annual salary of $5,220,000.00 as CEO at Vertex Pharmaceuticals. Learn More about Reshma Kewalramani's net worth.

How old is Reshma Kewalramani?

Dr. Kewalramani is currently 50 years old. There are 6 older executives and no younger executives at Vertex Pharmaceuticals. Learn More on Reshma Kewalramani's age.

What is Reshma Kewalramani's salary?

As the CEO of Vertex Pharmaceuticals Incorporated, Dr. Kewalramani earns $5,220,000.00 per year. Learn More on Reshma Kewalramani's salary.

How do I contact Reshma Kewalramani?

The corporate mailing address for Dr. Kewalramani and other Vertex Pharmaceuticals executives is 50 NORTHERN AVENUE, BOSTON MA, 02210. Vertex Pharmaceuticals can also be reached via phone at (617) 341-6100 and via email at [email protected]. Learn More on Reshma Kewalramani's contact information.

Has Reshma Kewalramani been buying or selling shares of Vertex Pharmaceuticals?

Reshma Kewalramani has not been actively trading shares of Vertex Pharmaceuticals within the last three months. Most recently, Reshma Kewalramani sold 7,828 shares of the business's stock in a transaction on Monday, July 17th. The shares were sold at an average price of $355.00, for a transaction totalling $2,778,940.00. Following the completion of the sale, the chief executive officer now directly owns 118,906 shares of the company's stock, valued at $42,211,630. Learn More on Reshma Kewalramani's trading history.

Who are Vertex Pharmaceuticals' active insiders?

Vertex Pharmaceuticals' insider roster includes David Altshuler (EVP), Kristen Ambrose (CAO), Stuart Arbuckle (COO), Sangeeta Bhatia (Director), Jonathan Biller (EVP), Joshua Boger (Director), Carmen Bozic (CMO), Reshma FASN (M.D.), Reshma Kewalramani (CEO), Yuchun Lee (Director), Jeffrey Leiden (Chairman), Joy Liu (SVP), Margaret McGlynn (Director), Michael Parini (EVP), Amit Sachdev (EVP), Bruce Sachs (Director), Bastiano Sanna (EVP), Paul Silva (CAO), Ian Smith (COO), Ourania Tatsis (EVP), and Charles Wagner, Jr. (CFO). Learn More on Vertex Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Vertex Pharmaceuticals?

During the last year, insiders at the pharmaceutical company sold shares 42 times. They sold a total of 161,940 shares worth more than $57,208,488.37. The most recent insider tranaction occured on February, 20th when EVP Ourania Tatsis sold 480 shares worth more than $201,979.20. Insiders at Vertex Pharmaceuticals own 0.4% of the company. Learn More about insider trades at Vertex Pharmaceuticals.

Information on this page was last updated on 2/20/2024.

Reshma Kewalramani Insider Trading History at Vertex Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/17/2023Sell7,828$355.00$2,778,940.00118,906View SEC Filing Icon  
4/27/2023Sell3,317$339.08$1,124,728.36126,652View SEC Filing Icon  
1/25/2023Sell10,000$315.05$3,150,500.0089,598View SEC Filing Icon  
8/15/2022Sell11,689$305.06$3,565,846.3499,598View SEC Filing Icon  
6/24/2022Sell11,689$291.30$3,405,005.70111,153View SEC Filing Icon  
8/19/2021Buy10,000$195.65$1,956,500.0069,511View SEC Filing Icon  
2/25/2020Sell3,634$233.45$848,357.3030,260View SEC Filing Icon  
2/18/2020Sell1,183$243.51$288,072.3334,341View SEC Filing Icon  
11/25/2019Sell4,692$219.37$1,029,284.0417,790View SEC Filing Icon  
11/8/2019Sell509$199.00$101,291.0013,607View SEC Filing Icon  
10/30/2019Sell3,057$199.00$608,343.0016,155View SEC Filing Icon  
10/22/2019Sell638$189.00$120,582.0013,098View SEC Filing Icon  
5/15/2019Sell241$165.41$39,863.8113,736View SEC Filing Icon  
2/19/2019Sell1,488$186.94$278,166.7214,038View SEC Filing Icon  
10/8/2018Sell2,305$186.95$430,919.751,909View SEC Filing Icon  
See Full Table

Reshma Kewalramani Buying and Selling Activity at Vertex Pharmaceuticals

This chart shows Reshma Kewalramani's buying and selling at Vertex Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Vertex Pharmaceuticals Company Overview

Vertex Pharmaceuticals logo
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations. The company's pipeline includes VX-522, a CF mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial; and VX-864 for treatment of AAT deficiency, which is in Phase 2 clinical trial. In addition, it provides VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sell the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies or pharmacy chains, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Affinia Therapeutics; Arbor Biotechnologies, Inc.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Obsidian Therapeutics, Inc.; Verve Therapeutics; Skyhawk Therapeutics; and Ribometrix, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $430.11
Low: $429.07
High: $434.50

50 Day Range

MA: $421.68
Low: $400.25
High: $446.08

2 Week Range

Now: $430.11
Low: $283.60
High: $448.40

Volume

749,859 shs

Average Volume

1,604,307 shs

Market Capitalization

$111.10 billion

P/E Ratio

30.97

Dividend Yield

N/A

Beta

0.36